New VA/DoD obesity guideline gives semaglutide and tirzepatide its top recommendation
The update backs the drugs alongside lifestyle programs instead of after they fail, and advises against stopping them once they work, a shift for millions of veterans.
Recap by typeshit. Full story at U.S. Medicine.